Scholar Rock Holding Corp (SRRK)
$48.39
$1.94
(4.18%)
As on 08-May-2026 16:00EDT
Market cap
$5,620 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
22.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
0.4
-
Book Value
$2.1
-
EPS
$-3.3
-
Face value
--
-
Shares outstanding
119,301,886
8 Years Aggregate
CFO
$-540.40 Mln
EBITDA
$-655.64 Mln
Net Profit
$-654.45 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Scholar Rock Holding Corp (SRRK)
| 9.9 | -3.0 | 8.9 | 62.9 | 83.4 | 9.5 | -- |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Scholar Rock Holding Corp (SRRK)
| 1.9 | 128.3 | 107.7 | -63.6 | -48.8 | 268.2 | -42.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Scholar Rock Holding Corp (SRRK)
|
48.4 | 5,620.3 | 0.0 | -377.9 | -- | -123.1 | -- | 22.6 |
| 72.7 | 11,082.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 49.5 | 18.5 | |
| 76.9 | 9,312.5 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 48.2 | 12,241.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.2 | |
| 95.7 | 12,229.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 8.5 | 8,776.8 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 305.7 | 8,519.4 | 389.1 | 204.8 | 41.5 | 18.9 | 38.7 | 6.6 | |
| 510.0 | 12,443.8 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 424.0 | 12,189.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.9 | 19.9 | |
| 330.0 | 9,422.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.7 |
Shareholding Pattern
View DetailsAbout Scholar Rock Holding Corp (SRRK)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding... of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142 Read more
-
President, CEO & Director
Dr. Jay Thomas Backstrom M.D., M.P.H.
-
President, CEO & Director
Dr. Jay Thomas Backstrom M.D., M.P.H.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Scholar Rock Holding Corp (SRRK)
What is the current share price of Scholar Rock Holding Corp (SRRK) Today?
The share price of Scholar Rock Holding Corp (SRRK) is $48.39 (NASDAQ) as of 08-May-2026 16:00 EDT. Scholar Rock Holding Corp (SRRK) has given a return of 83.43% in the last 3 years.
What is the current PB & PE ratio of Scholar Rock Holding Corp (SRRK)?
Since, TTM earnings of Scholar Rock Holding Corp (SRRK) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.40
|
20.64
|
|
2024
|
-17.55
|
11.72
|
|
2023
|
-9.41
|
6.93
|
|
2022
|
-4.12
|
2.09
|
|
2021
|
-6.97
|
5.34
|
What is the 52 Week High and Low of Scholar Rock Holding Corp (SRRK)?
The 52-week high and low of Scholar Rock Holding Corp (SRRK) are Rs 51.63 and Rs 27.07 as of 09-May-2026.
What is the market cap of Scholar Rock Holding Corp (SRRK)?
Scholar Rock Holding Corp (SRRK) has a market capitalisation of $ 5,620 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Scholar Rock Holding Corp (SRRK)?
Before investing in Scholar Rock Holding Corp (SRRK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.